Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added. Dose-dense regimens [more]
The more we learn about biological variations and changes within a tumour the more daunting becomes the challenge of personalising therapies. On the road towards personalised cancer therapies, the tasks of identifying new targets and [more]
When every additional day of life matters on the one hand, and the interests of a multibillion dollar industry are at stake on the other, promoting an informed debate about reimbursement policies can be quite [more]
When Ignace Vergote opted to specialise in gynaecological oncology, his country wasn’t ready, and he’s been waiting for the world to catch up with him ever since. Professor Ignace Vergote is a busy man. Arranging [more]
As more cancer patients survive longer, the need for rehabilitation services is rising up the political agenda, driven by patients who want their lives back, and by policy makers who want people to get back [more]
From 1989 to 2003, 709 phase III trials evaluating systemic cancer treatment were presented at ASCO meetings. Tam and collaborators have now reported that 9% of these trials were never published, and 13% were published [more]
The optimal treatment for patients with advanced-stage Hodgkin lymphoma is an ongoing controversy. A recent trial seemed to answer some of the important open questions in the field; however, closer examination of the data indicates [more]